A Multi-Target Approach for Identifying Natural Inhibitors of Metabolic Syndrome Proteins (AMPK, PPAR-Γ, IRS-1) Using Molecular Docking and in-Silico Screening

Metabolic syndrome is a complex cardiometabolic disorder driven by coordinated dysregulation of energy balance, insulin signaling, and lipid metabolism. Central regulatory proteins—including AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor-γ (PPAR-γ), and insulin receptor substrate-1 (IRS-1) - represent interconnected molecular nodes within this network, yet current therapeutic strategies largely rely on single-target modulation. Natural products offer structurally diverse scaffolds capable of engaging multiple targets, providing a rational basis for multi-target drug discovery. In this study, a systematic in silico multi-target screening strategy was employed to evaluate phytochemicals derived from Hyptis verticillata against AMPK, PPAR-γ, and IRS-1. Molecular docking was performed using AutoDock Vina against crystallographic structures of AMPK and PPAR-γ, while a homology-modeled structure of IRS-1 was utilized. Binding affinities and protein–ligand interaction profiles were analyzed, followed by in silico assessment of drug-likeness and pharmacokinetic properties using SwissADME. Docking analyses revealed binding energies ranging from −3.8 to −8.6 kcal/mol across the targets. Dehydropodophyllotoxin, oleanolic acid, cadina-4,10(15)-dien-3-one, aromadendr-1(10)-en-9-one, and squalene consistently exhibited favorable binding across multiple proteins. Interaction mapping indicated that ligand stabilization was dominated by hydrophobic and π-alkyl interactions within functionally relevant binding regions. Pharmacokinetic profiling suggested acceptable oral drug-likeness for several top-ranking compounds, particularly oleanolic acid. Collectively, these findings identify H. verticillata phytochemicals as promising multi-target molecular scaffolds relevant to metabolic regulation. While the results reflect predicted molecular recognition rather than functional modulation, this work establishes a robust computational framework for prioritizing natural compounds for experimental validation and supports the utility of multi-target in silico approaches in metabolic syndrome drug discovery.

Metabolic syndrome; Multi-target drug discovery; Molecular docking; AMPK; PPAR-γ; IRS-1; Phytochemicals; ADMET profiling

1. Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... & Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120(16), 1640–1645. [Google Scholar] [Crossref]

2. Ashraf, N., Zhang, Z., & Xu, Z. (2019). Limitations and challenges of pharmacotherapy in metabolic syndrome. Journal of Diabetes Research, 2019, 1–12. [Google Scholar] [Crossref]

3. Grundy, S. M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26(4), 364–373. [Google Scholar] [Crossref]

4. Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251–262. [Google Scholar] [Crossref]

5. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. [Google Scholar] [Crossref]

6. Li, X., Li, Q., Li, Y., & Tang, S. (2020). Natural products as modulators of metabolic syndrome. Frontiers in Pharmacology, 11, 578. [Google Scholar] [Crossref]

7. Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799–806. [Google Scholar] [Crossref]

8. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334–395. [Google Scholar] [Crossref]

9. Tontonoz, P., & Spiegelman, B. M. (2008). Fat and beyond: The diverse biology of PPARγ. Annual Review of Biochemistry, 77, 289–312. [Google Scholar] [Crossref]

10. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., ... & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. [Google Scholar] [Crossref]

11. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. [Google Scholar] [Crossref]

12. Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. In Chemical Biology (pp. 243–250). Humana Press. [Google Scholar] [Crossref]

13. Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies, 1(4), 337–341. [Google Scholar] [Crossref]

14. Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799–806. [Google Scholar] [Crossref]

15. Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. [Google Scholar] [Crossref]

• Artificial Intelligence in Pharmacology, Drug Safety and Toxicity
• Seroprevalence and Associated Risk Factors of Treponema Pallidum Infection among Pregnant Women Attending Antenatal Clinics in Lokoja, Kogi State
• In Silico Evaluation of Hyptis Verticillata-Derived Phytochemicals Targeting Estrogen Receptor Alpha (Erα) and Progesterone Receptor in Hormone-Dependent Breast Cancer
• A Review Article on AI in Personalized Medicine & Novel Pharamacology
• Leech Therapy (Hirudotherapy): A Comprehensive Systematic Review of Pharmacological Constituents, Mechanisms of Action, Therapeutic Applications, and Safety